Docetaxel(D) versus docetaxel plus gemcitabine(DG) for second-line treatment of non-small cell lung cancer (NSCLC) : Results of a JCOG randomized trial (JCOG0104)
Phase 3
- Conditions
- on-small cell Lung Cancer
- Registration Number
- JPRN-C000000027
- Lead Sponsor
- Japan Clinical Oncology Group(JCOG)
- Brief Summary
See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 284
Inclusion Criteria
Not provided
Exclusion Criteria
1) Symptomatic brain metastasis 2) Double cancer 3) Superior vena cava syndrom 4) Massive pleural effusion or ascitis 5) Spiral compression 6) Severe hypertension 7) Diabetis melitus treated with insulin 8) Concommitant infectious disease excluded hepatic fever 9) Interstitial lung disease 10) Hypersinsitivity to Polysorbate 80 11) Need to treatment with steroid, ketoconazole, nifedipine or erithromycin 12) Psycologic illness 13) Women during pregbnancy or lacteted
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method